The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combined activity of the cancer metabolism inhibitor MPC-8640 and 5-fluorouracil in xenograft models.
Vijay R. Baichwal
Employment or Leadership Position - Myrexis
Stock Ownership - Myrexis
Chad Bradford
Employment or Leadership Position - Myrexis
Stock Ownership - Myrexis
J. Scott Patton
Employment or Leadership Position - Myrexis
Stock Ownership - Myrexis
Leslie Reeves
Employment or Leadership Position - Myrexis
Stock Ownership - Myrexis
Lynn DeMie
Employment or Leadership Position - Myrexis
Stock Ownership - Myrexis
Lori Fotheringham
Employment or Leadership Position - Myrexis
Stock Ownership - Myrexis
Orvelin Roman
Employment or Leadership Position - Myrexis
Stock Ownership - Myrexis
Thomas B Douce
Employment or Leadership Position - Myrexis
Stock Ownership - Myrexis
Brita Brown
Employment or Leadership Position - Myrexis
Stock Ownership - Myrexis
Robert O. Carlson
Employment or Leadership Position - Myrexis
Stock Ownership - Myrexis